Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Cipla
Deloitte
Harvard Business School
Julphar
Covington
Fish and Richardson
Baxter
Mallinckrodt

Generated: May 27, 2018

DrugPatentWatch Database Preview

OGEN 1.25 Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Ogen 1.25 patents expire, and when can generic versions of Ogen 1.25 launch?

Ogen 1.25 is a drug marketed by Pharmacia And Upjohn and is included in one NDA.

The generic ingredient in OGEN 1.25 is estropipate. There are two drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the estropipate profile page.
Summary for OGEN 1.25
Drug patent expirations by year for OGEN 1.25
Synonyms for OGEN 1.25
[(1S,10R,11S,15S)-15-METHYL-14-OXOTETRACYCLO[8.7.0.0(2),?.0(1)(1),(1)?]HEPTADECA-2,4,6-TRIEN-5-YL]OXIDANESULFONIC ACID; PIPERAZINE
[(1S,10R,11S,15S)-15-METHYL-14-OXOTETRACYCLO[8.7.0.0(2),?.0(1)(1),(1)?]HEPTADECA-2(7),3,5-TRIEN-5-YL]OXIDANESULFONIC ACID; PIPERAZINE
[(8R,9S,13S,14S)-13-methyl-17-oxidanylidene-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate; piperazine
[(8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate; piperazine
[(9S,14S)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate; piperazine
17-oxoestra-1,3,5(10)-trien-3-yl hydrogen sulfate - piperazine (1:1)
280E377
29080-16-8
3-(Sulfooxy)-estra-1,3,5(10)-trien-17-one : piperazine (1:1)
7280-37-7
A837628
AC1L2MV7
AC1NR4O7
AKOS024457702
AM20080957
AX8127548
BCP9000662
C-22322
C18H22O5S.C4H10N2
CAS-7280-37-7
CC-27537
CCG-220688
CHEBI:4873
CHEMBL1200980
CM14419
Conjugated estrogens: piperazine estrone sulfate
CS-4818
CTK8F9509
D00948
D03IUY
DR002699
DSSTox_CID_3005
DSSTox_GSID_23005
DSSTox_RID_76828
DTXSID3023005
EINECS 230-696-3
Estra-1,3,5(10)-trien-17-one 3-sulphate, compound with piperazine (1:1)
Estra-1,3,5(10)-trien-17-one, 3-(sulfooxy)-, compd. with piperazine (1:1)
Estrone hydrogen sulfate compound with piperazine (1:1)
Estrone sulfate piperazine salt
Estrone, hydrogen sulfate, compd. with piperazine (1:1)
Estrone, hydrogen sulfate, compd. with piperazine (1:1) (8CI)
Estropipate
Estropipate (USP)
Estropipate [USAN]
Estropipate [USP:INN:BAN]
Estropipate, >=98% (HPLC), powder
Estropipate, United States Pharmacopeia (USP) Reference Standard
Harmogen
HMS1570I17
HMS2097I17
HMS2232O19
HY-B1361
LS-64829
MFCD00867399
MLS002153957
MolPort-006-167-814
NCGC00016682-02
Ogen
OGEN .625
Ogen (TN)
OGEN 2.5
OGEN 5
Ortho-Est
piperazine (8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl sulfate
Piperazine estrone sulfate
Piperazine estronesulfate
Piperazine oestrone sulphate
Piperazine, compd. with 3-(sulfooxy)estra-1,3,5(10)-trien-17-one (1:1)
Piperazine, compd. with 3-(sulfooxy)estra-1,3,5(10)-trien-17-one (1:1) (9CI)
Piperazine, compd. with estrone hydrogen sulfate (1:1)
Piperazine, compd. with estrone hydrogen sulfate (1:1) (8CI)
piperazine; sulfuric acid [(8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] ester
PL000390
PL068206
PubChem22728
SCHEMBL21577
SMR001233296
ST24048920
Sulestrex
SVI38UY019
Tox21_113350
UNII-SVI38UY019

US Patents and Regulatory Information for OGEN 1.25

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pharmacia And Upjohn OGEN 1.25 estropipate TABLET;ORAL 083220-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Chinese Patent Office
Medtronic
US Department of Justice
Accenture
Citi
Deloitte
US Army
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.